Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 open-label, dose escalation study of INB03 in patients with metastatic cancer with increased inflammatory biomarkers in peripheral blood

Trial Profile

Phase 1 open-label, dose escalation study of INB03 in patients with metastatic cancer with increased inflammatory biomarkers in peripheral blood

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INB 03 (Primary)
  • Indications Advanced breast cancer; Anal cancer; Cholangiocarcinoma; Colon cancer; Duodenal cancer; Gastric cancer; Gastrointestinal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors INmune Bio
  • Most Recent Events

    • 24 Oct 2019 Status changed from recruiting to completed.
    • 05 Aug 2019 According to an INmune Bio media release, 11 of 12 patients have been enrolled in one of three dosing cohorts of INB03 (0.3, 1.0 and 3.0 mg/kg) to date.
    • 05 Aug 2019 According to an INmune Bio media release, positive preliminary data from the first two cohorts were released and these data will be followed by a final report later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top